Navigation Links
Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Date:3/25/2009

CRANBURY, N.J., March 25 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the issuance on March 10, 2009 of United States Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of Use." The patent covers the tartrate salt form of isofagomine, the active ingredient in the Company's investigational drug Plicera(TM) (afegostat tartrate), and its use for the treatment of Gaucher disease. The patent will expire in 2027.

John F. Crowley, President and CEO of Amicus, commented, "The issuance of this patent further strengthens our protection in the United States for Plicera in Gaucher and is one example of our ongoing efforts to establish a comprehensive intellectual property portfolio for our development programs and our pharmacological chaperone technology platform."

Plicera is currently being studied in an ongoing Phase 2 study in patients naive to enzyme replacement therapy. This six-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that enrollment has been completed for the study and the Company expects the results to be available in the third quarter of 2009.

Amicus is developing Plicera as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the collaboration, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 ... Überwachungssystem für kongestive Herzinsuffizienz (CHF) in seiner ...     Die ... neuartiges Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz ... sie ein Finanzierungsvorhaben über 5 Mio. USD ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... DESI are increasing in applications as their ... research firm Kalorama Information.  Kalorama Information says ... MS) is the most powerful tool in ... (mass spec; MS) through its traditional techniques ...
(Date:2/26/2015)... Feb. 26, 2015  AbbVie (NYSE: ... studies in its neuroscience and oncology development programs ... th American Academy of Neurology annual meeting ... April 18-25. The accepted abstracts feature results from ... to investigational treatments in AbbVie,s pipeline. Presentations will ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... VEGAS, Jan. 9, 2012 BASIS Science, Inc. ( www.mybasis.com ... and health tracker, the Basis™ B1 band, will be demoing ... showing its web-based personal dashboard for the first time. The ... people information about their everyday health and wellness. ...
... the nation,s largest independent specialty pharmacy in the ... rights from Regeneron for its new drug EYLEA™ ... 2011, EYLEA (aflibercept) Injection was approved by the ... the treatment of neovascular (wet) age-related macular degeneration ...
Cached Medicine Technology:BASIS Science to Demo Basis Band at 2012 International CES; Reveals Design of Web Dashboard 2Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection 2
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Altec ... LLP (BPW) has been chosen as their doc-link for ... GP, CRM and other complimentary solutions for their customers ... working with credit unions. Altec and BPW have worked ... doc-link’s integration to Dynamics GP. , “We are so ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Pipette.com ... Vortex-Genie® 2 , price is only valid until the ... lab technicians looking for a vortex mixer that allows ... Industries was founded in 1954 and is headquartered in ... mixers & shakers, as well as other rockers, incubators, ...
(Date:2/27/2015)... 27, 2015 In New York City, ... by providing free dental care from his Sheepshead Bay­neighborhood ... with Dentistry from the Heart, and will be hosting ... first 50 patients who are in need of fillings, ... will have access to high­quality service of Dr. Umanoff's ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The V ... cancer research funding organizations, is excited to announce numerous ... to participate and many long-standing partnerships highlight The V ... focus on expanding ways for all to get involved. ... to cutting-edge cancer research, The V Foundation has funded ...
(Date:2/27/2015)... 2015 Royal River Natural Foods, a locally-owned ... study that found adults who got the most magnesium were ... compared to those who got the least magnesium, with the ... The report is part of the March 2015 issue of ... Natural Foods publishes free each month for the Freeport community ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2
... is needed to achieve dignified care for older people, says ... welfare of older people who live in care homes has ... and Miles Witham at the University of Dundee. ... dignity, but people of all ages have a fundamental right ...
... A new study in The American Journal of Gastroenterology ... intestinal tract is attacked in those who suffer ... determines whether the patient will eventually require surgical treatment. ... to appear more frequently in the small intestine, rather ...
... in BJOG: An International Journal of Obstetrics and Gynaecology ... and placental abruption during the subsequent pregnancies of ... ,Placental praevia is defined as the implantation of ... the cervix. Placenta abruption is the premature separation of ...
... and women at risk for alcohol dependence are more likely ... investigators at Washington University School of Medicine in St. ... end up as problem drinkers. ,Alcoholism is ... non-alcoholics, but it isn't as common as it might be. ...
... allergy is increasingly common, affecting one in 70 schoolchildren, available ... the allergy. ,A joint team of ... and St Thomas' hospital, are taking up a seven-year study ... study. ,The babies being studied are between four ...
... diabetic patients of the superbug MRSA - by treating their ... and his team used green bottle fly larvae to treat ... and found all but one were cured within a mean ... for the conventional treatment. ,Professor Boulton, who published ...
Cached Medicine News:Health News:Major Change Needed to Achieve Dignified Care for Older People 2Health News:Placental Problems in Women Linked With Caesarean Section 2Health News:Spouse may "drive You to Drink" but also can Protect You from Alcohol 2Health News:UK Scientists to Undertake Seven Year Study of Peanut Allergy 2Health News:Maggots Rid Patients of MRSA 2
... etched into the gel tray which casts a ... cables, three 7x10 cm gel trays, 4 aluminum ... The Chameleon can accomodate up to five combs ... of 120 samples with a 2.5 cm path ...
... of a Separation-Control unit for system control ... gel staining. The optional PhastTransfer Kit quickly ... unit. Electrophoresis is performed on a thermostatic ... 0 to +70 C. Multi-step programming capability ...
... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
Medicine Products: